JP2010509914A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010509914A5 JP2010509914A5 JP2009537154A JP2009537154A JP2010509914A5 JP 2010509914 A5 JP2010509914 A5 JP 2010509914A5 JP 2009537154 A JP2009537154 A JP 2009537154A JP 2009537154 A JP2009537154 A JP 2009537154A JP 2010509914 A5 JP2010509914 A5 JP 2010509914A5
- Authority
- JP
- Japan
- Prior art keywords
- array
- substance
- item
- binder
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 23
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 22
- 239000011230 binding agent Substances 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- 229940126530 T cell activator Drugs 0.000 claims description 4
- 239000002981 blocking agent Substances 0.000 claims description 4
- 108090001008 Avidin Proteins 0.000 claims description 3
- 102000009410 Chemokine receptor Human genes 0.000 claims description 3
- 108050000299 Chemokine receptor Proteins 0.000 claims description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 102000037865 fusion proteins Human genes 0.000 claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims description 3
- 230000002297 mitogenic effect Effects 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 15
- 238000003491 array Methods 0.000 claims 4
- 230000005867 T cell response Effects 0.000 claims 3
- 238000004132 cross linking Methods 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 241000486679 Antitype Species 0.000 claims 2
- 239000004005 microsphere Substances 0.000 claims 2
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 claims 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 claims 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 claims 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 claims 1
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 claims 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 239000011324 bead Substances 0.000 description 11
- 230000005291 magnetic effect Effects 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 101710160107 Outer membrane protein A Proteins 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920003232 aliphatic polyester Polymers 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/601,446 US7592431B2 (en) | 2004-02-26 | 2006-11-17 | Biodegradable T-cell Activation device |
| PCT/US2007/023478 WO2008063421A2 (en) | 2006-11-17 | 2007-11-07 | Biodegradable t-cell activation device and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010509914A JP2010509914A (ja) | 2010-04-02 |
| JP2010509914A5 true JP2010509914A5 (enExample) | 2011-12-22 |
Family
ID=39430286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009537154A Pending JP2010509914A (ja) | 2006-11-17 | 2007-11-07 | 生分解性ｔ細胞活性化デバイスおよび方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7592431B2 (enExample) |
| EP (1) | EP2089056A4 (enExample) |
| JP (1) | JP2010509914A (enExample) |
| CA (1) | CA2669544A1 (enExample) |
| IL (1) | IL198782A0 (enExample) |
| WO (1) | WO2008063421A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7435592B2 (en) | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
| US7592431B2 (en) * | 2004-02-26 | 2009-09-22 | Immunovative Therapies, Ltd. | Biodegradable T-cell Activation device |
| EP1776583A4 (en) | 2004-02-26 | 2009-04-29 | Immunovative Therapies Ltd | PROCESSES FOR THE PREPARATION OF T CELLS FOR CELL THERAPY |
| SG194753A1 (en) | 2011-05-03 | 2013-12-30 | Immunovative Therapies Ltd | Induction of il-12 using immunotherapy |
| KR20140099328A (ko) | 2011-05-03 | 2014-08-11 | 이뮤노베이티브 테라피스, 엘티디. | 생세포를 포함하는 생물학적 약물을 처리하기 위한 용기 또는 주사기 |
| WO2013036585A1 (en) * | 2011-09-06 | 2013-03-14 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t cell subsets using biocompatible solid substrates with tunable rigidity |
| RU2746407C1 (ru) | 2012-02-23 | 2021-04-13 | Стейдж Селл Терапеутикс Гмбх | Хроматографическое выделение клеток и других сложных биологических материалов |
| EP2711418B1 (en) * | 2012-09-25 | 2017-08-23 | Miltenyi Biotec GmbH | Method for polyclonal stimulation of T cells by flexible nanomatrices |
| ES2612918T3 (es) | 2013-07-10 | 2017-05-19 | Miltenyi Biotec Gmbh | Método para inducir la proliferación de células asesinas naturales por nanomatrices móviles |
| WO2015148512A1 (en) | 2014-03-24 | 2015-10-01 | Qt Holdings Corp | Shaped articles including hydrogels and methods of manufacture and use thereof |
| DK3189132T3 (da) | 2014-09-04 | 2020-08-10 | Stemcell Tech Inc | Opløselige antistofkomplekser til T-celle- eller NK-celle-aktivering og -ekspansion |
| PH12017502013B1 (en) | 2015-05-07 | 2022-07-22 | Agenus Inc | Anti-ox40 antibodies and methods of use thereof |
| US9790467B2 (en) | 2015-09-22 | 2017-10-17 | Qt Holdings Corp | Methods and compositions for activation or expansion of T lymphocytes |
| MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
| MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
| MA45426A (fr) | 2015-10-22 | 2019-05-01 | Juno Therapeutics Gmbh | Procédés, kits, agents et appareils de transduction |
| SG11201804265XA (en) | 2015-12-02 | 2018-06-28 | Agenus Inc | Antibodies and methods of use thereof |
| US10988724B2 (en) | 2016-05-05 | 2021-04-27 | Southwest Research Institute | Three-dimensional bioreactor for cell expansion and related applications |
| US10294454B2 (en) | 2016-08-24 | 2019-05-21 | General Electric Company | Methods and kits for cell activation |
| MA46053A (fr) | 2016-08-26 | 2019-07-03 | Juno Therapeutics Inc | Procédés de dénombrement de particules présentes dans une composition cellulaire |
| CA3041340A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| IL250916A0 (en) * | 2017-03-02 | 2017-06-29 | Geiger Benjamin | Methods for growing t cells in culture and their use |
| WO2019169194A1 (en) | 2018-02-28 | 2019-09-06 | Juno Therapeutics, Inc. | Methods for detecting particles present in a cell composition |
| US11149244B2 (en) | 2018-04-04 | 2021-10-19 | Southwest Research Institute | Three-dimensional bioreactor for T-cell activation and expansion for immunotherapy |
| CN108835031B (zh) * | 2018-06-14 | 2020-03-17 | 华南农业大学 | 一种选育高繁殖性能种公猪的方法 |
| CN108841789A (zh) * | 2018-06-19 | 2018-11-20 | 中国人民解放军陆军军医大学第二附属医院 | 一种体外活化小鼠t淋巴细胞的方法 |
| SG11202102986XA (en) | 2018-09-24 | 2021-04-29 | Southwest Res Inst | Three-dimensional bioreactors |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2439003A1 (fr) | 1978-10-20 | 1980-05-16 | Anvar | Nouvelles pieces d'osteosynthese, leur preparation et leur application |
| US5766920A (en) | 1982-08-11 | 1998-06-16 | Cellcor, Inc. | Ex vivo activation of immune cells |
| AU7873187A (en) | 1986-08-08 | 1988-02-24 | University Of Minnesota | Method of culturing leukocytes |
| AU2635088A (en) | 1987-12-04 | 1989-06-08 | Du Pont Merck Pharmaceutical Company, The | Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) * | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5126132A (en) | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
| US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
| AU5729294A (en) * | 1992-11-25 | 1994-06-22 | Tanox Biosystems, Inc. | Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules |
| WO1995004817A1 (en) | 1993-08-06 | 1995-02-16 | Cytel Corporation | Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl |
| IL107483A0 (en) | 1993-11-03 | 1994-02-27 | Yeda Res & Dev | Bone marrow transplantation |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| AU720201B2 (en) | 1995-03-08 | 2000-05-25 | Scripps Research Institute, The | Antigen presenting system and methods for activation of T-cells |
| DE19545257A1 (de) | 1995-11-24 | 1997-06-19 | Schering Ag | Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln |
| WO1997046256A1 (en) | 1996-05-23 | 1997-12-11 | The Scripps Research Institute | Mhc class ii antigen-presenting systems and methods for activating cd4+ t cells |
| WO1998024483A2 (en) | 1996-12-03 | 1998-06-11 | Osteobiologics, Inc. | Biodegradable polymeric film |
| US6194207B1 (en) | 1997-01-31 | 2001-02-27 | Hemosol Inc. | Methods for the selective expansion of lymphocytes by in vitro cultivation |
| ATE412383T1 (de) | 1997-05-30 | 2008-11-15 | Osteobiologics Inc | Faserverstärkte,poröse,biologisch abbaubare implantatvorrichtung |
| AU1395499A (en) | 1997-11-10 | 1999-05-31 | Arch Development Corporation | Methods for treatment of tumors and tumor cells using (ex vivo) activated t cells |
| JP2001054563A (ja) | 1999-07-12 | 2001-02-27 | Isotis Bv | 縫合糸 |
| KR20030032922A (ko) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | 세포의 동시 자극 및 농축 |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US20030119185A1 (en) | 2000-02-24 | 2003-06-26 | Xcyte Therapies, Inc. | Activation and expansion of cells |
| WO2002017935A2 (en) | 2000-08-31 | 2002-03-07 | Emory University | A method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease |
| US6626950B2 (en) | 2001-06-28 | 2003-09-30 | Ethicon, Inc. | Composite scaffold with post anchor for the repair and regeneration of tissue |
| US20040258661A1 (en) | 2001-10-31 | 2004-12-23 | Daniel Fowler | Generation of use of tc1 and tc2 cells |
| US7105580B2 (en) | 2001-12-06 | 2006-09-12 | University Of Washington | Porous structures useful for growing living tissue, and methods of manufacture |
| US20030175272A1 (en) | 2002-03-07 | 2003-09-18 | Medcell Biologics, Inc. | Re-activated T-cells for adoptive immunotherapy |
| DE10230223A1 (de) | 2002-07-04 | 2004-01-22 | Tegenero Ag | Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern |
| JP2004062924A (ja) | 2002-07-25 | 2004-02-26 | Matsushita Electric Ind Co Ltd | 半導体記憶装置及びその初期化方法 |
| US7402431B2 (en) | 2004-03-01 | 2008-07-22 | Immunovative Therapies, Ltd. | T-cell therapy formulation |
| US7435592B2 (en) | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
| US7371228B2 (en) | 2003-09-19 | 2008-05-13 | Medtronic Vascular, Inc. | Delivery of therapeutics to treat aneurysms |
| US7592431B2 (en) | 2004-02-26 | 2009-09-22 | Immunovative Therapies, Ltd. | Biodegradable T-cell Activation device |
| EP1776583A4 (en) * | 2004-02-26 | 2009-04-29 | Immunovative Therapies Ltd | PROCESSES FOR THE PREPARATION OF T CELLS FOR CELL THERAPY |
| US7446099B2 (en) | 2004-02-27 | 2008-11-04 | Nitto Denko Corporation | Compositions and methods for biodegradable polymer-peptide mediated transfection |
| CA2530514C (en) * | 2004-03-01 | 2017-01-31 | Immunovative Therapies, Ltd. | Cell therapy formulation method and composition |
| CA2557436A1 (en) | 2004-03-05 | 2005-09-29 | The Trustees Of Columbia University In The City Of New York | Polymer-ceramic-hydrogel composite scaffold for osteochondral repair |
-
2006
- 2006-11-17 US US11/601,446 patent/US7592431B2/en not_active Expired - Lifetime
-
2007
- 2007-11-07 JP JP2009537154A patent/JP2010509914A/ja active Pending
- 2007-11-07 EP EP07867384A patent/EP2089056A4/en not_active Ceased
- 2007-11-07 CA CA002669544A patent/CA2669544A1/en not_active Abandoned
- 2007-11-07 WO PCT/US2007/023478 patent/WO2008063421A2/en not_active Ceased
-
2009
- 2009-05-17 IL IL198782A patent/IL198782A0/en active IP Right Grant
- 2009-07-31 US US12/533,668 patent/US8012750B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010509914A5 (enExample) | ||
| CN106687584B (zh) | 用于t细胞或nk细胞活化和扩增的可溶性抗体复合物 | |
| EP2109669B1 (en) | Methods for reversibly binding a biotin compound to a support | |
| Eksteen et al. | Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis | |
| JP2019526273A5 (enExample) | ||
| Kumar et al. | Affinity fractionation of lymphocytes using a monolithic cryogel | |
| CA2080118C (en) | Antigen/anti-antigen cleavage | |
| ATE169409T1 (de) | Positive und positive/negative zellselektion vermittelt durch peptiofreisetzung | |
| JP4628110B2 (ja) | イムノクロマトグラフ法用試験具 | |
| JP2005500304A5 (enExample) | ||
| CA2264925A1 (en) | Purification of antigen-specific t cells | |
| AU778569B2 (en) | Methods of modification of selected cells in a magnetic cell separation column | |
| Wallace et al. | Cytotoxic T cell recognition of Epstein‐Barr virus‐infected B cells. II. Blocking studies with monoclonal antibodies to HLA determinants | |
| US20140170727A1 (en) | Affinity medium using fixed whole cells | |
| JPH05507792A (ja) | 粒子表面からリガンドを除去するための方法 | |
| US5518882A (en) | Immunological methods of component selection and recovery | |
| US4108975A (en) | Radioimmunoassay system | |
| Liu et al. | Cell growth on immobilized cell-growth factor; 4: interaction of fibroblast cells with insulin immobilized on poly (memthyl methacyrlate) membrane | |
| JPWO2019141774A5 (enExample) | ||
| WO1991001368A1 (en) | Hapten/anti-hapten affinity linking in cell separation | |
| JP7045924B2 (ja) | 細胞捕捉用フィルター膜及びその使用 | |
| US5672687A (en) | Magnetic protein conjugates, a process for the preparation thereof, and the use thereof | |
| WIGZELL | Cellular immunosorbents | |
| CN201673155U (zh) | 微通道芯片检测装置 | |
| CN112912103B (zh) | 多价蛋白质复合物 |